Mayo Clinic College of Medicine, Division of Medical Oncology, 200 First St. SW Rochester, MN 55905, USA.
Expert Opin Investig Drugs. 2009 Jul;18(7):1025-33. doi: 10.1517/13543780903055049.
The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.
IGF 通路在许多人类恶性肿瘤中对癌细胞的增殖、存活和对抗肿瘤治疗的耐药性起着重要作用。因此，干扰这条通路是许多正在研究的药物的靶点。Cixutumumab 是一种针对 IGF-1R 的单克隆抗体，利用了这一概念。在这篇综述中，我们总结了关于该药物的临床前、药理学和早期临床数据，并讨论了该药物可能对人类癌症未来治疗的影响。
